Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer
ChiCTR2200067005Phase 2Recruiting
- Sponsor
- Changde First People's Hospital
- Start
- Dec 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in triple-negative breast cancer (TNBC), sponsored by Changde First People's Hospital. Primary endpoint: Total pathological complete response rate. Started Dec 2022; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2200067005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067005.